Programme 2 – PISTER

On October 18th, the French PDX network and the Organoids research group organised, with the support of the SIRIC ILIAD and the CRCI²NA, a hybrid colloquium : Modeling tumor development and [...]

What if acting on the cells surrounding the tumour could improve the effectiveness of treatments? On 14 September 2022, a team from the SIRIC ILIAD specialising in breast cancer published a [...]

The SIRIC ILIAD Partners Committee met on Monday 17 October 2022 to present the results of the 5 years of labelling. A week ago, the fifth meeting of the SIRIC ILIAD Partners Committee took place [...]

Last August, Professor Philippe Moreau, haematologist and director of SIRIC ILIAD, published a scientific article in the prestigious New England Journal of Medicine, alongside some thirty [...]

Since May 2022, Sara Gandolfi has joined the ranks of the SIRIC ILIAD teams as a post-doctoral researcher. She has joined team 11 of the CRCI²NA, to study a bone marrow cancer, multiple myeloma. [...]

Last June, Professors Philippe Moreau and Cyrille Touzeau, both haematologists and researchers at SIRIC ILIAD, published a scientific article in Blood, THE specialist haematology journal. Every [...]

The Centre de Recherches en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI²NA) offers a postdoctoral position in cell biology. Contract duration : A one-year (renewable) Research [...]

In January 2022, at the end of its five-year mandate, the CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes – Angers) evolves and becomes the CRCI²NA. Philippe Juin and [...]

Doctor Jean-Sébastien Frenel, an oncologist at the Institut de Cancérologie de l’Ouest, has benefited from “protected medical time” since 1 November 2021, to enable him to [...]

Following the mid-term evaluation of the SIRICs (SIte de Recherche Intégrée sur le Cancer), the scientific committee of the French National Cancer Institute (INCa) underlines in its scientific [...]